Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.26.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Year Ended December 31, 

($ in thousands)

  ​ ​ ​

2025

  ​ ​ ​

2024

EmrosiTM

​

$

14,745

​

$

—

Qbrexza®

​

​

25,014

​

​

25,114

Accutane®

​

​

12,882

​

​

19,407

Foam franchise products (Amzeeq® & Zilxi®)

​

​

5,859

​

​

6,652

Other / legacy

​

​

2,739

​

​

3,961

Total product revenues

​

$

61,239

​

$

55,134

Schedule of other revenue

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Year Ended December 31, 

($ in thousands)

​

2025

  ​ ​ ​

2024

Milestone payment from Cutia

​

$

—

​

$

1,000

Cutia supply agreement

 

​

606

​

​

—

Royalties on sales of Amzeeq by Cutia

​

​

13

​

​

—

Total other revenue

​

$

619

​

$

1,000